Buprenorphine: A newer drug for treating neonatal abstinence syndrome

Neonatal Network

Volumn 31, Issue 3, 2012, Pages 178-183

  Bell, Susan Givens ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; NARCOTIC AGENT; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST;

HUMAN; NEWBORN; OPIATE SUBSTITUTION TREATMENT; REVIEW; WITHDRAWAL SYNDROME;

ANALGESICS, OPIOID; BUPRENORPHINE; HUMANS; INFANT, NEWBORN; NARCOTIC ANTAGONISTS; NARCOTICS; NEONATAL ABSTINENCE SYNDROME; OPIATE SUBSTITUTION TREATMENT;

EID: 84865581207     PISSN: 07300832     EISSN: 15392880     Source Type: Journal    
DOI: 10.1891/0730-0832.31.3.178     Document Type: Article

References (13)

1. Burgos AE, Burke BL Jr,. Neonatal abstinence syndrome. NeoReviews. 2009; 10 (5): e222-e228. http://dx.doi.org/10.1542/neo.10-5-e222
2. Wong S, Ordean A, Kahan M; Society of Obstetricians and Gynecologists of Canada,. SOGC clinical practice guidelines: substance use in pregnancy: no. 256, April 2011. Int J Gynaecol Obstet. 2011; 114 (2): 190-192.
3. O'Grady MJ, Hopewell J, White MJ,. Management of neonatal abstinence syndrome: a national survey and review of practice. Arch Dis Child Fetal Neonatal Ed. 2009; 94 (4): F249-F252. http://dx.doi.org/10.1136/adc.152769
4. Sarkar S, Donn SM,. Management of neonatal abstinence syndrome in neonatal intensive care units: a national survey. J Perinatol. 2006; 26 (1): 15-17. http://dx.doi.org/10.1038/sj.jp.7211427 (Pubitemid 43135249)
5. Reckitt Benckiser Pharmaceutical, Inc. Buprenex Injectable-RX only-Schedule III. 2007. Available at: http://www.naabt.org/documents/buprenex- PI.pdf. Accessed October 1, 2011.
6. United States Department of Health and Human Services, Substance Abuse and Mental Health Services Administration. About buprenorphine therapy. Available at: http://buprenorphine.samhsa.gov/about.html. Accessed October 2, 2011.
7. Substance Abuse and Mental Health Services Administration. Results from the 2010 National Survey on Drug Use and Health; Summary of National Findings. Rockville, MD: Substance Abuse and Mental Health Administration; 2011. NSDUH Series H-41, HHS Publication No. (SMA) 11-4658.
8. Barrett DA, Simpson J, Ruter N, Kurihara-Bergstrom T, Shaw PN, Davis SS,. The pharmacokinetics and physiological effects of buprenorphine infusion in premature neonates. Br J Clin Pharmacol. 1993; 36 (3): 215-219. (Pubitemid 23275338)
9. Kraft WL, Gibson E, Dysart K, et al. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. Pediatrics. 2008; 122 (3): e601-e607. http://dx.doi.org/10.1542/peds.2008-0571
10. Kraft WK, Dysart K, Greenspan JS, Gibson E, Kaltenbach K, Ehrlich ME,. Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome. Addiction. 2011; 106 (3): 574-580. http://dx.doi.org/10.1111/j.1360-0443.2010.03170.x
11. Jones HE,. Commentary on Kraft et al. (2011): Treatment of neonatal abstinence syndrome-morphine, buprenorphine, and beyond. Addiction. 2011; 106 (3): 581-582. http://dx.doi.org/10.1111/j.1360-0443.2010.03236.x
12. National Institute on Drug Abuse. Topics in brief: prenatal exposure to drugs of abuse-May 2011. Available at: http://drugabuse.gov/sites/default/files/ prenatal.pdf.
13. National Alliance of Advocates for Buprenorphine Treatment. Thorough technical explanation of burprenorphine [sic]. Available at: http://www.naabt.org/education/technical-explanation-buprenorphine.cfm. Accessed November 18, 2011.